Clearmind Medicine Announces Publication of International Patent for Novel Therapy Targeting Weight Loss and Fatty Liver Disease
MWN-AI** Summary
Clearmind Medicine Inc. has announced the publication of an international patent application under the Patent Cooperation Treaty (PCT) for a groundbreaking therapy targeting weight loss and metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as fatty liver disease. The innovative treatment combines Clearmind's proprietary compound 5-methoxy-2-aminoindane (MEAI) with Palmitoylethanolamide (PEA), a collaboration facilitated by NeuroThera Labs Inc. This combination aims to address the global health issues of obesity and MASLD, with obesity affecting over 890 million adults and MASLD impacting around 30% of the adult population worldwide.
The market for weight loss medications is predicted to grow substantially, from approximately $37 billion in 2025 to an estimated $226 billion by 2035, driven by increasing awareness of obesity and the need for effective treatment alternatives. Clearmind's MEAI-PEA therapy distinguishes itself as a non-hallucinogenic neuroplastogen option, potentially offering a safer and more cost-efficient solution than current GLP-1 agonists.
Dr. Adi Zuloff-Shani, the CEO of Clearmind, emphasized the company's mission to develop transformative therapies for underserved health conditions. The dual approach in addressing obesity and liver health aims to meet the growing demand for effective, tolerable treatments. Clearmind, a clinical-stage biotech company listed on Nasdaq under the symbol "CMND," boasts a robust intellectual property portfolio with nineteen patent families, including 31 granted patents, and continues to seek further innovation and acquisition of intellectual property.
With its promising developments, Clearmind is positioning itself as a key player in the biotech sector, focusing on solutions for significant health challenges like obesity and MASLD.
MWN-AI** Analysis
Clearmind Medicine's recent announcement regarding the publication of an international patent for its innovative combination therapy targeting obesity and metabolic dysfunction-associated steatotic liver disease (MASLD) signifies a notable advancement in the biotech sector. The proprietary blend of MEAI and Palmitoylethanolamide (PEA) not only holds promise for addressing significant global health issues but also positions Clearmind within a burgeoning market projected to surpass $200 billion by 2035.
From an investment perspective, this development could enhance Clearmind's appeal, particularly as healthcare stakeholders increasingly seek effective, non-hallucinogenic solutions for obesity and MASLD. The reported mechanism of action suggests that this therapy could serve as a safer and more cost-effective alternative to existing GLP-1 agonists, which are currently popular yet often come with substantial side effects and high costs.
The global weight loss drugs market is experiencing rapid growth, and the increasing prevalence of obesity further underlines the urgency for innovative treatments. Clearmind's strategy aligns well with this trend, as the need for effective, tolerable, and accessible treatments becomes more pronounced. Moreover, the company’s overall commitment to developing neuroplastogen therapies for various underserved health problems adds depth to its investment thesis, indicating a diversified portfolio approach.
However, potential investors should remain cautious. The biotech space carries inherent risks, particularly at clinical stages where regulatory approval can profoundly impact valuation. Given the competitive landscape and Clearmind's current standing, investors should closely monitor clinical trial results and broader market dynamics.
Should Clearmind successfully navigate these challenges and bring its product to market, it could capture a substantial share of a rapidly expanding industry, presenting significant opportunities for stakeholders. Continued evaluation of market trends and company developments is essential for making informed investment decisions.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Innovative non-hallucinogenic treatment combines MEAI with Palmitoylethanolamide to address obesity and metabolic dysfunction-associated steatotic liver disease, tapping into a rapidly growing market projected to exceed $200 billion by 2035
Vancouver, Canada, March 10, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced the publication of an international patent application under the Patent Cooperation Treaty (PCT) for a novel combination therapy aimed at treating weight loss and metabolic dysfunction-associated steatotic liver disease (MASLD, formerly known as fatty liver disease). This novel therapy integrates Clearmind’s proprietary 5-methoxy-2-aminoindane (MEAI) with Palmitoylethanolamide (PEA), provided through its collaboration with NeuroThera Labs Inc. (TSXV: NTLX), a subsidiary of SciSparc Ltd. (Nasdaq: SPRC).
The patent publication highlights the potential of this MEAI-PEA combination to offer a safe, non-hallucinogenic neuroplastogen treatment for two major global health challenges: obesity, affecting over 890 million adults worldwide, and MASLD, impacting approximately 30% of the global adult population. Moreover, due to the presumed mechanism of action of the combination, this therapeutic option may offer a safer, easier and more cost effective option than GLP-1s agonists for obesity and MASLD.
"The publication of this international patent is part of our mission to develop innovative, proprietary and transformative therapies for underserved metabolic and neurological conditions," said Dr. Adi Zuloff-Shani, CEO of Clearmind Medicine. "By combining our MEAI platform with PEA from our partners at NeuroThera Labs, we are positioning ourselves to address the escalating demand for effective, tolerable and safe treatments in the obesity and liver health space. This comes at a time when the global weight loss drugs market is experiencing rapid growth, which was valued at approximately $37 billion in 2025 and is forecasted to reach $226 billion by 2035, driven by increasing awareness of obesity as a chronic disease and the need for innovative alternatives to GLP-1 agonists."
About Clearmind Medicine Inc.
Clearmind is a clinical-stage neuroplastogens pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements.
The Company’s intellectual portfolio currently consists of nineteen patent families, including 31 granted patents. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.
Shares of Clearmind are listed for trading on Nasdaq under the symbol "CMND".
For further information, visit: https://www.clearmindmedicine.com or contact:
Investor Relations
invest@clearmindmedicine.com
Telephone: (604) 260-1566
US: CMND@crescendo-ir.com
General Inquiries
Info@Clearmindmedicine.com
www.Clearmindmedicine.com
Forward-Looking Statements:
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses the potential of this MEAI-PEA combination to offer a safe, non-hallucinogenic neuroplastogen treatment for obesity and MASLD, its mission to develop innovative, proprietary and transformative therapies for underserved metabolic and neurological conditions, how this therapeutic option may offer a safer, easier and more cost effective option than GLP-1s agonists for obesity and MASLD, how it is position itself to address the escalating demand for effective, tolerable treatments in the obesity and liver health space and the expected growth of the global weight loss drugs market.
Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s annual report on Form 20-F for the fiscal year ended October 31, 2025 and subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Clearmind is not responsible for the contents of third-party websites.
FAQ**
How does the collaboration with SciSparc Ltd. (SPRC) enhance Clearmind's development of the MEAI-PEA combination therapy for obesity and metabolic dysfunction-associated steatotic liver disease (MASLD)?
In what ways does the MEAI-PEA combination therapy potentially outperform GLP-1 agonists, and how might this impact Clearmind's market positioning as they enter the obesity treatment sector?
Given the forecasted growth of the global weight loss drugs market to $226 billion by 2035, how does Clearmind plan to capitalize on this trend in conjunction with their partnership with SciSparc Ltd. (SPRC)?
What steps is Clearmind taking to ensure the successful commercialization of the MEAI-PEA therapy, and how does the involvement of SciSparc Ltd. (SPRC) factor into their overall strategy?
**MWN-AI FAQ is based on asking OpenAI questions about SciSparc Ltd. (NASDAQ: SPRC).
NASDAQ: SPRC
SPRC Trading
-17.43% G/L:
$3.8438 Last:
21,429 Volume:
$3.89 Open:
